Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of “Moderate Buy” from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $56.33.

Several equities analysts have recently commented on the stock. Scotiabank upped their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Finally, Raymond James restated an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th.

Insider Buying and Selling

In related news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of AGIO. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at approximately $37,000. Quest Partners LLC acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares during the last quarter. CWM LLC grew its stake in shares of Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals in the third quarter valued at approximately $146,000.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $38.97 on Wednesday. Agios Pharmaceuticals has a 1-year low of $20.96 and a 1-year high of $62.58. The firm has a market cap of $2.22 billion, a PE ratio of 3.43 and a beta of 0.80. The company has a 50-day moving average of $50.02 and a two-hundred day moving average of $46.76.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.